Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by University of Milan.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Gian Vincenzo Zuccotti, University of Milan
ClinicalTrials.gov Identifier:
NCT01512784
First received: January 13, 2012
Last updated: January 18, 2012
Last verified: January 2012

January 13, 2012
January 18, 2012
October 2011
July 2013   (final data collection date for primary outcome measure)
type specific antibody titers for HPV types 6, 11, 16 and 18 at one month after completion of HPV vaccine series (T3) in HIV infected subjects vs. healthy subjects [ Time Frame: one month +/- 10 days after 3° vaccine dose ] [ Designated as safety issue: No ]
Immunogenicity of quadrivalent human papillomavirus vaccine (Gardasil®) will be assessed by evaluation of type-specific antibody development for HPV types 6, 11, 16 and 18 from seronegative status at baseline (T0) to seropositive status at one month after the completion of HPV vaccine series (T3), compared with the same immunogenicity testings performed in healthy subjects matched for sex and age.
Same as current
Complete list of historical versions of study NCT01512784 on ClinicalTrials.gov Archive Site
  • antibody HPV titers to types 6, 11, 16 and 18, one month after the first two vaccination series (T1 and T2) in HIV-infected subjects vs healthy subjects [ Time Frame: one month +/- 10 days after 1°vaccine dose and month+/- 10 days after 2° vaccine dose ] [ Designated as safety issue: No ]
    Antibody titers for HPV types 6, 11, 16 and 18 will be evaluated one month after the first (T1) and second (T2) vaccination dose in HIV-infected adolescents and young adults compared with the same immunological testings in healthy adolescents and young adults.
  • antibody titers to HPV types 6, 11, 16 and 18 at month 12(T4)and 18 (T5)from baseline (T0). [ Time Frame: 12 months +/- 10 days and 18 months +/-10 days from baseline ] [ Designated as safety issue: No ]
    To assess long-term immunogenicity of quadrivalent human papillomavirus vaccine (Gardasil® in HIV-infected and healthy subjects by evaluation of persistence of HPV antibody titers to types 6, 11, 16 and 18 at month 12 (T4) and 18(T5) from baseline (T0).
  • local and systemic adverse events [ Time Frame: 7 days after each vaccination dose ] [ Designated as safety issue: Yes ]
    Safety and tolerability of three doses of quadrivalent human papillomavirus vaccine (Gardasil ®) in HIV-infected and healthy subjects will be assessed by evaluating the occurrence and severity of local and systemic adverse events during the 7 days after each vaccination dose.
  • HIV viral load and lymphocyte CD4+ count [ Time Frame: baseline (T0), one month after each vaccination dose (T1, T2 and T3) and at month 12 (T4) and 18 (T5) from baseline. ] [ Designated as safety issue: No ]
    Longitudinal monitoring of HIV-viral load and lymphocyte CD4+ count will be conducted in HIV-infected subjects from baseline (T0), throughout the study: one month after each vaccination dose (T1, T2, T3) and at month 12 and 18 from baseline (T4, T5).
  • lymphoproliferative responses, cytokine production and immunophenotype analysis of lymphocyte subpopulations [ Time Frame: baseline (T0), one month after 1° vaccination dose (T1) and one month after 3° vaccination dose (T3). ] [ Designated as safety issue: No ]

    To evaluate in a subgroup of subjects (20 HIV-infected and 20 healthy) the following immunological parameters at baseline and at 1 month after 1° vaccination dose (T1) and at 1 month after 3° vaccination dose (T3):

    lymphoproliferative responses to HPV-16 L1 from PBMCs in peripheral blood

    Immunophenotype analysis of lymphocyte subpopulations in peripheral blood

    Cytokine production from peripheral lymphocyte subpopulations at baseline and after stimulation with HPV-16 recombinant protein L1.

Same as current
Not Provided
Not Provided
 
Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults
Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults vs. Healthy Adolescents and Young Adults: Non-randomized Controlled Clinical Trial

Infection with human immunodeficiency virus (HIV) is an important risk factor for HPV infection and the development of HPV-associated lesions in female and male anogenital tract. Data on safety and immunogenicity of quadrivalent human papillomavirus vaccine in HIV-infected population are few. The present study is a non-randomized controlled clinical trial with the primary objective to determine safety ad immunogenicity of quadrivalent human papillomavirus vaccine (Gardasil®) in HIV-infected female and male adolescents and young adults.

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • HPV
  • HIV
  • Biological: Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)

    Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).

    Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:

    First dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.

    Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:

    Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms.

  • Biological: Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)

    Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).

    Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:

    first dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.

    Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:

    Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms.

  • Experimental: HIV-infected adolescents and young adults
    female and male HIV-infected subjects aged from 13-27 years old
    Intervention: Biological: Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)
  • Active Comparator: healthy adolescents and young adults
    female and male healthy adolescents and young adults aged 13-27 years
    Intervention: Biological: Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
July 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • For both HIV-infected and healthy subjects:

    • Subjects aged 13-27 years, females and males
    • Written informed consent from parent or guardian if applicable (age<18 years)
  • For HIV-infected subjects:

    • HIV-positive
    • Asymptomatic subjects (generalized lymphadenopathy is accepted)
    • Lymphocyte CD4+ count > or equal to 350 cells/mm3
  • For subjects receiving HAART:

    • Good compliance to therapy
    • At least two suppressed viral loads HIV-RNA (<37copies/ml9 during 6 months prior to enrollment.

Exclusion Criteria:

  • For female subjects (both HIV-infected and healthy)
  • Pregnancy or breastfeeding
  • Total hysterectomy. Participants who have undergone partial hysterectomy and have a cervix are not excluded.
  • For both females and males (HIV-infected and healthy):
  • Prior vaccination with quadrivalent HPV vaccine Gardasil before study entry.
  • History of severe allergic reaction after previous vaccination or hypersensitivity to any vaccine component.
  • Any serious chronic or progressive disease (other than HIV) according to the judgment of the investigator:
  • Acute infection requiring therapy or fever at time of enrollment
  • Chronic autoimmune or oncologic disease receiving chemotherapy
  • Concomitant therapies (other than HAART):
  • Chronic therapy (for more than 14 days consecutively) with immunosuppressive or immunomodulating agents or chemotherapy during the 6 months prior to study entry.
  • Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation prior to study entry.
  • Use of investigational agents within 4 weeks prior to study enrollment.
  • Current drug or alcohol use or dependence.
  • Documented history of non-adherence to antiretroviral treatment regimen within 12 months prior to study entry.
Both
13 Years to 27 Years
Yes
Contact: Gian Vincenzo Zuccotti, Head Paediatric Department 0039/02/39042253 gianvincenzo.zuccotti@unimi.it
Contact: Gian Vincenzo Zuccotti, Head Paediatrics 0039/02/39042253 gianvincenzo.zuccotti@unimi.it
Italy
 
NCT01512784
HLS04/2011
Not Provided
Gian Vincenzo Zuccotti, University of Milan
University of Milan
Not Provided
Principal Investigator: Gian Vincenzo Zuccotti, Head of Paediatric Department L.Sacco Hospital, via G.B Grassi, 74 20157 Milano, Italy
University of Milan
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP